With major investments from Johnson & Johnson, Bristol Myers Squibb, and AbbVie showcasing pharma’s commitment to anti-psychosis therapies, the Innovation in Psychosis Therapeutics Summit was a unique opportunity to engage biotech and pharma leaders. Â
Senior decision-makers sought innovative solutions for R&D challenges as the industry moves beyond atypical antipsychotics. By showcasing your expertise, you could have played a key role in advancing psychosis R&D and accelerating the delivery of life-changing therapies.
Attendee Insights | Services Needed to Advance Psychosis R&D:
Preclinical CROs with unique assays, moving beyond D2 focused receptorsÂ
Clinical CROs who can tackle the lack of adherence in a psychotic patient population and provide sufficient oversightÂ
Biomarker technology to help de-risk moving from preclinical to clinical trials Â
Imaging technology to increase translational validity of preclinical modelsÂ
Uncovering the underlying mechanism of psychosis to enhance drug discovery Â
And more! – Explore a broad range of cutting-edge solutions to accelerate psychosis R&DÂ
Â
Why Partner?
Whether you're aiming to secure new partnerships, showcase your innovations, or grow your influence, there are unparalleled opportunities to…Â
Showcase Your Cutting-Edge Technologies: Present your state-of-the-art innovations to a highly engaged audience of decision-makers across discovery, translational, and clinical development. Â
Enhance Brand Visibility and Establish Leadership: Position yourself as the go-to partner for psychosis organizations seeking experts in preclinical and clinical outsourcing.Â
Engage with Key Stakeholders: Network one-on-one to gain insights and understand the primary markets R&D challenges and tailor your solutions to meet their specific needs.Â